0001104659-24-006381.txt : 20240125
0001104659-24-006381.hdr.sgml : 20240125
20240125060016
ACCESSION NUMBER: 0001104659-24-006381
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L
CENTRAL INDEX KEY: 0001225198
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 24558448
MAIL ADDRESS:
STREET 1: C/O ACHILLION PHARMACEUTICALS, INC.
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 6462005278
MAIL ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Galena Biopharma, Inc.
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
4
1
tm243935-6_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-22
0
0001390478
SELLAS Life Sciences Group, Inc.
SLS
0001225198
VAN NOSTRAND ROBERT L
C/O SELLAS LIFE SCIENCES GROUP, INC.,
7 TIMES SQUARE, SUITE 2503
NEW YORK
NY
10036
1
0
0
0
0
Common Stock
2024-01-22
4
A
0
6000
0.00
A
10400
D
Stock Option (Right to Buy)
0.5195
2024-01-22
4
A
0
10000
0
A
2034-01-22
Common Stock
10000
10000
D
The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
/s/ Robert L. Van Nostrand
2024-01-24